Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Jinqi, Xue"'
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-41 (2024)
Abstract Drug resistance represents a significant obstacle in cancer treatment, underscoring the need for the discovery of novel therapeutic targets. Ubiquitin-specific proteases (USPs), a subclass of deubiquitinating enzymes, play a pivotal role in
Externí odkaz:
https://doaj.org/article/3cebdcfe7db644e0b812dd990f468e10
Autor:
Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-27 (2023)
Abstract Background Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity of tumor cells and increases
Externí odkaz:
https://doaj.org/article/051fb92e013844e9a0e1e93d201c1b90
Autor:
Hongli Gao, Jianqiao Yin, Ce Ji, Xiaopeng Yu, Jinqi Xue, Xin Guan, Shuang Zhang, Xun Liu, Fei Xing
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-22 (2023)
Abstract Tumors have evolved in various mechanisms to evade the immune system, hindering the antitumor immune response and facilitating tumor progression. Immunotherapy has become a potential treatment strategy specific to different cancer types by u
Externí odkaz:
https://doaj.org/article/a2388da6c7a544dbbfed463e0222ce30
Autor:
Shiwen Huo, Jinqi Xue, Shuo Wang, Huilian Shan, Guanglei Chen, Nan Niu, Yimin Wang, Fang Qiu, Yi Zhao, Fei Xing, Xinyu Zheng, Wei Tu, Ke Li, Hai Zhao, Meiyue Tang, Qianshi Xu, Chao Liu, Yafei Zhao, Xiaofan Jiang, Zheng Pang, Keliang Zhang, Dianlong Zhang, Zhe‐Sheng Chen, Caigang Liu
Publikováno v:
MedComm, Vol 5, Iss 3, Pp n/a-n/a (2024)
Abstract Triple‐positive breast cancer (TPBC) poorly responds to current standard neoadjuvant therapy (trastuzumab plus pertuzumab and chemotherapy). Our previous MUKDEN 01 study showed a promising total pathological complete response (tpCR) rate o
Externí odkaz:
https://doaj.org/article/90fd47107198425c8ce96e8bc7172b7d
Autor:
Jiawen Bu, Yixiao Zhang, Sijin Wu, Haonan Li, Lisha Sun, Yang Liu, Xudong Zhu, Xinbo Qiao, Qingtian Ma, Chao Liu, Nan Niu, Jinqi Xue, Guanglei Chen, Yongliang Yang, Caigang Liu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract Failure to achieve complete elimination of triple negative breast cancer (TNBC) stem cells after adjuvant therapy is associated with poor outcomes. Aldehyde dehydrogenase 1 (ALDH1) is a marker of breast cancer stem cells (BCSCs), and its enz
Externí odkaz:
https://doaj.org/article/4a6a3bc37dc04129b0d0a57674aa4a99
Autor:
Guanglei Chen, Xi Gu, Jinqi Xue, Xu Zhang, Xiaopeng Yu, Yu Zhang, Ailin Li, Yi Zhao, Guijin He, Meiyue Tang, Fei Xing, Jianqiao Yin, Xiaobo Bian, Ye Han, Shuo Cao, Chao Liu, Xiaofan Jiang, Keliang Zhang, Yan Xia, Huajun Li, Nan Niu, Caigang Liu, On behalf of the Northeastern Clinical Research Alliance of Oncology (NCRAO)
Publikováno v:
eLife, Vol 12 (2023)
Background: Emerging data have supported the immunostimulatory role of radiotherapy, which could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but suboptimal effect of ICI and chemotherapy in triple-negati
Externí odkaz:
https://doaj.org/article/4d40ffdb0c304d388f1adabf0f97596c
Autor:
Fei Xing, Hongli Gao, Guanglei Chen, Lisha Sun, Jiayi Sun, Xinbo Qiao, Jinqi Xue, Caigang Liu
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-18 (2023)
Abstract Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterized by invasive growth, rapid metastasis and chemoresistance. Trastuzumab is an effective treatment for HER2+ breast cancer; however, trastuzumab resistance
Externí odkaz:
https://doaj.org/article/55d793deec8c4ed0b87df053f085fb2f
Publikováno v:
World Journal of Surgical Oncology, Vol 20, Iss 1, Pp 1-17 (2022)
Abstract Background Loss of G2-specific E3-like (G2E3) protein sensitizes tumor cells to chemotherapy. However, the role of G2E3 in breast cancer development and patient’s prognosis is unclear. Here, we explored the expression, prognostic significa
Externí odkaz:
https://doaj.org/article/3f88e1dfe6524f92998985168abafea9
Autor:
Nan Niu, Fang Qiu, Qianshi Xu, Guijin He, Xi Gu, Wenbin Guo, Dianlong Zhang, Zhigao Li, Yi Zhao, Yong Li, Ke Li, Hao Zhang, Peili Zhang, Yuanxi Huang, Gangling Zhang, Hongbin Han, Zhengang Cai, Pengfei Li, Hong Xu, Guanglei Chen, Jinqi Xue, Xiaofan Jiang, Alireza Hamidian Jahromi, Jinshi Li, Yu Zhao, Eduardo de Faria Castro Fleury, Shiwen Huo, Huajun Li, Guy Jerusalem, Domenico Tripodi, Tong Liu, Xinyu Zheng, Caigang Liu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Neoadjuvant therapy is recommended for patients with locally advanced breast cancer. Here the authors report the results of a phase 2 clinical trial of oral neoadjuvant therapy with pyrotinib (pan-HER tyrosine kinase inhibitor), letrozole (aromatase
Externí odkaz:
https://doaj.org/article/1d9c37ba0fbf4148af08531c29508fb7
Autor:
Xinbo Qiao, Yixiao Zhang, Zhan Zhang, Nan Niu, Haonan Li, Lisha Sun, Qingtian Ma, Jiawen Bu, Jinchi Liu, Guanglei Chen, Jinqi Xue, Yongliang Yang, Caigang Liu
Publikováno v:
Asian Journal of Pharmaceutical Sciences, Vol 18, Iss 3, Pp 100814- (2023)
The altered lysosomal function can induce drug redistribution which leads to drug resistance and poor prognosis for cancer patients. V-ATPase, an ATP-driven proton pump positioned at lysosomal surfaces, is responsible for maintaining the stability of
Externí odkaz:
https://doaj.org/article/b25602f28e464d2ba28c01e6b6e459c0